Literature DB >> 31895219

Molecular Magnetic Resonance Imaging of Fibrin Deposition in the Liver as an Indicator of Tissue Injury and Inflammation.

Iliyana Atanasova1, Mozhdeh Sojoodi2, Helena S Leitão3, Sergei Shuvaev1, Carlos F G C Geraldes4, Ricard Masia5, Alexander S Guimaraes1, Kenneth K Tanabe2, Bryan C Fuchs2, Peter Caravan.   

Abstract

RATIONALE AND
OBJECTIVES: Liver inflammation is associated with nonalcoholic steatohepatitis and other pathologies, but noninvasive methods to assess liver inflammation are limited. Inflammation causes endothelial disruption and leakage of plasma proteins into the interstitial space and can result in extravascular coagulation with fibrin deposition. Here we assess the feasibility of using the established fibrin-specific magnetic resonance probe EP-2104R for the noninvasive imaging of fibrin as a marker of liver inflammation.
METHODS: Weekly 100 mg/kg diethylnitrosamine (DEN) dosing was used to generate liver fibrosis in male rats; control animals received vehicle. Magnetic resonance imaging at 1.5 T with EP-2104R, a matched non-fibrin-binding control linear peptide, or the collagen-specific probe EP-3533 was performed at 1 day or 7 days after the last DEN administration. Imaging data were compared with quantitative histological measures of fibrosis and inflammation.
RESULTS: After 4 or 5 DEN administrations, the liver becomes moderately fibrotic, and fibrosis is the same if the animal is killed 1 day (Ishak score, 3.62 ± 0.31) or 7 days (Ishak score, 3.82 ± 0.25) after the last DEN dose, but inflammation is significantly higher at 1 day compared with 7 days after the last DEN dose (histological activity index from 0-4, 3.54 ± 0.14 vs 1.61 ± 0.16, respectively; P < 0.0001). Peak EP-2104R signal enhancement was significantly higher in animals imaged at 1 day post-DEN compared with 7 days post-DEN or control rats (29.0% ± 3.2% vs 22.4% ± 2.0% vs 17.0% ± 0.2%, respectively; P = 0.017). Signal enhancement with EP-2104R was significantly higher than control linear peptide at 1 day post-DEN but not at 7 days post-DEN indicating specific fibrin binding during the inflammatory phase. Collagen molecular magnetic resonance with EP-3533 showed equivalent T1 change when imaging rats 1 day or 7 days post-DEN, consistent with equivalent fibrosis.
CONCLUSIONS: EP-2104R can specifically detect fibrin associated with inflammation in a rat model of liver inflammation and fibrosis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31895219      PMCID: PMC7935409          DOI: 10.1097/RLI.0000000000000631

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  43 in total

Review 1.  Coagulation cascade proteases and tissue fibrosis.

Authors:  R C Chambers; G J Laurent
Journal:  Biochem Soc Trans       Date:  2002-04       Impact factor: 5.407

2.  Platelets and fibrin in progression of liver disease: friends or foes?

Authors:  T Lisman
Journal:  J Thromb Haemost       Date:  2014-12-06       Impact factor: 5.824

Review 3.  Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis.

Authors:  Takeshi Yokoo; Suraj D Serai; Ali Pirasteh; Mustafa R Bashir; Gavin Hamilton; Diego Hernando; Houchun H Hu; Holger Hetterich; Jens-Peter Kühn; Guido M Kukuk; Rohit Loomba; Michael S Middleton; Nancy A Obuchowski; Ji Soo Song; An Tang; Xinhuai Wu; Scott B Reeder; Claude B Sirlin
Journal:  Radiology       Date:  2017-09-11       Impact factor: 11.105

Review 4.  Coagulation and coagulation signalling in fibrosis.

Authors:  Paul F Mercer; Rachel C Chambers
Journal:  Biochim Biophys Acta       Date:  2013-01-05

5.  3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model.

Authors:  Christian T Farrar; Danielle K DePeralta; Helen Day; Tyson A Rietz; Lan Wei; Gregory Y Lauwers; Boris Keil; Arun Subramaniam; Anthony J Sinskey; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan
Journal:  J Hepatol       Date:  2015-05-25       Impact factor: 25.083

6.  CM-101: Type I Collagen-targeted MR Imaging Probe for Detection of Liver Fibrosis.

Authors:  Christian T Farrar; Eric M Gale; Richard Kennan; Ian Ramsay; Ricard Masia; Gunisha Arora; Kailyn Looby; Lan Wei; Jayashree Kalpathy-Cramer; Michelle M Bunzel; Chunlian Zhang; Yonghua Zhu; Taro E Akiyama; Michael Klimas; Shirly Pinto; Himashinie Diyabalanage; Kenneth K Tanabe; Valerie Humblet; Bryan C Fuchs; Peter Caravan
Journal:  Radiology       Date:  2017-11-20       Impact factor: 11.105

7.  Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.

Authors:  Kento Imajo; Takaomi Kessoku; Yasushi Honda; Wataru Tomeno; Yuji Ogawa; Hironori Mawatari; Koji Fujita; Masato Yoneda; Masataka Taguri; Hideyuki Hyogo; Yoshio Sumida; Masafumi Ono; Yuichiro Eguchi; Tomio Inoue; Takeharu Yamanaka; Koichiro Wada; Satoru Saito; Atsushi Nakajima
Journal:  Gastroenterology       Date:  2015-12-08       Impact factor: 22.682

8.  EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.

Authors:  Kirsten Overoye-Chan; Steffi Koerner; Richard J Looby; Andrew F Kolodziej; Stephan G Zech; Qing Deng; Jaclyn M Chasse; Thomas J McMurry; Peter Caravan
Journal:  J Am Chem Soc       Date:  2008-04-08       Impact factor: 15.419

9.  Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility.

Authors:  Josef Vymazal; Elmar Spuentrup; Gerardo Cardenas-Molina; Andrea J Wiethoff; Michael G Hartmann; Peter Caravan; Edward C Parsons
Journal:  Invest Radiol       Date:  2009-11       Impact factor: 6.016

10.  Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist.

Authors:  Derek J Erstad; Christian T Farrar; Sarani Ghoshal; Ricard Masia; Diego S Ferreira; Yin-Ching Iris Chen; Ji-Kyung Choi; Lan Wei; Phillip A Waghorn; Nicholas J Rotile; Chuantao Tu; Katherine A Graham-O'Regan; Mozhdeh Sojoodi; Shen Li; Yang Li; Guogiang Wang; Kathleen E Corey; Yat Sun Or; Lijuan Jiang; Kenneth K Tanabe; Peter Caravan; Bryan C Fuchs
Journal:  Hepatol Commun       Date:  2018-05-21
View more
  3 in total

Review 1.  Advances in functional and molecular MRI technologies in chronic liver diseases.

Authors:  Iris Y Zhou; Onofrio A Catalano; Peter Caravan
Journal:  J Hepatol       Date:  2020-06-22       Impact factor: 25.083

2.  Fibrin-targeting molecular MRI in inflammatory CNS disorders.

Authors:  Johannes Lohmeier; Rafaela V Silva; Anna Tietze; Matthias Taupitz; Takaaki Kaneko; Harald Prüss; Friedemann Paul; Carmen Infante-Duarte; Bernd Hamm; Peter Caravan; Marcus R Makowski
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-04       Impact factor: 10.057

3.  Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218.

Authors:  Yajuan Li; Songqi Gao; Hongfa Jiang; Nadia Ayat; Victoria Laney; Calin Nicolescu; Wenyu Sun; Michael F Tweedle; Zheng-Rong Lu
Journal:  Invest Radiol       Date:  2022-05-05       Impact factor: 10.065

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.